Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endometrial Neoplasms | 14 | 2024 | 1386 | 3.330 |
Why?
|
Sarcoma, Endometrial Stromal | 9 | 2023 | 93 | 2.720 |
Why?
|
Breast Neoplasms | 46 | 2024 | 21187 | 2.260 |
Why?
|
Uterine Neoplasms | 10 | 2023 | 1424 | 2.230 |
Why?
|
Mastitis | 2 | 2020 | 42 | 1.410 |
Why?
|
Soft Tissue Neoplasms | 5 | 2023 | 1166 | 1.370 |
Why?
|
Sarcoma | 6 | 2023 | 1806 | 1.320 |
Why?
|
Ovarian Neoplasms | 12 | 2024 | 4919 | 1.270 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2022 | 388 | 1.260 |
Why?
|
Uterine Cervical Neoplasms | 6 | 2024 | 2044 | 1.190 |
Why?
|
Breast | 12 | 2024 | 1976 | 1.170 |
Why?
|
Sclerosis | 2 | 2024 | 212 | 1.060 |
Why?
|
Carcinoma, Ductal, Breast | 6 | 2010 | 1093 | 1.040 |
Why?
|
Carcinoma, Lobular | 5 | 2010 | 480 | 1.040 |
Why?
|
Cystadenocarcinoma, Serous | 3 | 2020 | 480 | 1.030 |
Why?
|
Carcinoma | 3 | 2022 | 2340 | 1.000 |
Why?
|
Receptor, erbB-2 | 8 | 2024 | 2606 | 0.980 |
Why?
|
Carcinoma, Papillary | 2 | 2021 | 793 | 0.900 |
Why?
|
Carcinosarcoma | 2 | 2021 | 108 | 0.890 |
Why?
|
Immunohistochemistry | 20 | 2024 | 11119 | 0.860 |
Why?
|
Observer Variation | 5 | 2024 | 2623 | 0.850 |
Why?
|
Hydatidiform Mole | 2 | 2023 | 255 | 0.820 |
Why?
|
Hyperplasia | 2 | 2022 | 1154 | 0.760 |
Why?
|
Folate Receptor 1 | 1 | 2021 | 41 | 0.760 |
Why?
|
Receptor, trkC | 1 | 2021 | 63 | 0.730 |
Why?
|
Wilms Tumor | 2 | 2023 | 378 | 0.730 |
Why?
|
Basement Membrane | 1 | 2021 | 348 | 0.700 |
Why?
|
Granulomatous Mastitis | 1 | 2020 | 7 | 0.700 |
Why?
|
Corynebacterium Infections | 1 | 2020 | 27 | 0.690 |
Why?
|
Receptor, trkB | 1 | 2021 | 125 | 0.680 |
Why?
|
DNA Methylation | 5 | 2023 | 4432 | 0.680 |
Why?
|
Receptor, trkA | 1 | 2021 | 159 | 0.670 |
Why?
|
Fibrosarcoma | 1 | 2021 | 313 | 0.630 |
Why?
|
Tissue Array Analysis | 8 | 2019 | 551 | 0.610 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9442 | 0.600 |
Why?
|
Mammary Glands, Human | 4 | 2008 | 202 | 0.590 |
Why?
|
Gynecology | 1 | 2024 | 534 | 0.580 |
Why?
|
Neoplasm Staging | 10 | 2024 | 11262 | 0.580 |
Why?
|
Receptors, Estrogen | 5 | 2018 | 2252 | 0.580 |
Why?
|
Leiomyosarcoma | 4 | 2023 | 425 | 0.570 |
Why?
|
Gene Expression Profiling | 16 | 2020 | 9549 | 0.560 |
Why?
|
Pathology, Clinical | 1 | 2020 | 377 | 0.550 |
Why?
|
Adenocarcinoma, Mucinous | 2 | 2019 | 526 | 0.540 |
Why?
|
Repressor Proteins | 3 | 2022 | 2986 | 0.540 |
Why?
|
Gene Fusion | 5 | 2023 | 357 | 0.540 |
Why?
|
Female | 88 | 2024 | 397464 | 0.530 |
Why?
|
Precancerous Conditions | 3 | 2014 | 985 | 0.530 |
Why?
|
Adenocarcinoma | 3 | 2019 | 6401 | 0.530 |
Why?
|
Breast Neoplasms, Male | 1 | 2018 | 212 | 0.520 |
Why?
|
Hemangioma, Capillary | 1 | 2016 | 64 | 0.520 |
Why?
|
Oncogenes | 2 | 2020 | 1236 | 0.510 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 2016 | 133 | 0.500 |
Why?
|
Granuloma | 2 | 2015 | 329 | 0.490 |
Why?
|
Histoplasma | 1 | 2015 | 40 | 0.490 |
Why?
|
Proto-Oncogene Proteins | 3 | 2022 | 4528 | 0.490 |
Why?
|
Histoplasmosis | 1 | 2015 | 64 | 0.480 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 592 | 0.470 |
Why?
|
Prognosis | 21 | 2024 | 30044 | 0.450 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 5801 | 0.440 |
Why?
|
Tamoxifen | 1 | 2018 | 967 | 0.430 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1328 | 0.430 |
Why?
|
Germ-Line Mutation | 2 | 2021 | 1887 | 0.420 |
Why?
|
Lymphatic Metastasis | 6 | 2024 | 2916 | 0.410 |
Why?
|
Endometrial Stromal Tumors | 2 | 2023 | 46 | 0.400 |
Why?
|
Adrenal Glands | 1 | 2015 | 557 | 0.400 |
Why?
|
Humans | 101 | 2024 | 768887 | 0.400 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 2 | 2024 | 118 | 0.400 |
Why?
|
Endometrium | 1 | 2014 | 406 | 0.390 |
Why?
|
Diagnosis, Differential | 8 | 2024 | 13020 | 0.390 |
Why?
|
Fixatives | 1 | 2011 | 90 | 0.390 |
Why?
|
Aged, 80 and over | 19 | 2024 | 59738 | 0.380 |
Why?
|
Lymphoma | 1 | 2020 | 1900 | 0.380 |
Why?
|
Carcinoma, Endometrioid | 3 | 2023 | 277 | 0.380 |
Why?
|
Homeodomain Proteins | 2 | 2022 | 2431 | 0.380 |
Why?
|
Leg | 1 | 2016 | 1089 | 0.380 |
Why?
|
Neoplasm Invasiveness | 5 | 2024 | 3629 | 0.370 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 2 | 2023 | 78 | 0.360 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2023 | 2525 | 0.350 |
Why?
|
Tissue Fixation | 1 | 2011 | 245 | 0.350 |
Why?
|
Membrane Glycoproteins | 1 | 2021 | 3714 | 0.340 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 1535 | 0.330 |
Why?
|
Middle Aged | 37 | 2024 | 223740 | 0.320 |
Why?
|
Cervix Uteri | 4 | 2024 | 576 | 0.320 |
Why?
|
Teratoma | 2 | 2023 | 405 | 0.320 |
Why?
|
Neoplasm Metastasis | 3 | 2017 | 4926 | 0.310 |
Why?
|
Carrier Proteins | 1 | 2022 | 4940 | 0.310 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1483 | 0.310 |
Why?
|
Sarcoidosis | 1 | 2014 | 535 | 0.310 |
Why?
|
Pathology, Molecular | 1 | 2011 | 329 | 0.310 |
Why?
|
Nerve Tissue Proteins | 2 | 2020 | 4415 | 0.300 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2059 | 0.300 |
Why?
|
Cadherins | 2 | 2010 | 906 | 0.300 |
Why?
|
Giant Cell Tumors | 1 | 2008 | 89 | 0.300 |
Why?
|
Cystadenoma, Mucinous | 1 | 2008 | 62 | 0.300 |
Why?
|
Papillomavirus Infections | 2 | 2019 | 1640 | 0.290 |
Why?
|
Neutrophils | 1 | 2020 | 3785 | 0.280 |
Why?
|
Kidney Neoplasms | 2 | 2023 | 4300 | 0.280 |
Why?
|
Aged | 28 | 2024 | 171790 | 0.270 |
Why?
|
Microdissection | 1 | 2007 | 151 | 0.270 |
Why?
|
Leiomyoma | 2 | 2022 | 644 | 0.270 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1148 | 0.270 |
Why?
|
Adult | 35 | 2024 | 223818 | 0.270 |
Why?
|
Ki-67 Antigen | 3 | 2024 | 628 | 0.260 |
Why?
|
Disease-Free Survival | 4 | 2021 | 6856 | 0.260 |
Why?
|
BRCA1 Protein | 2 | 2013 | 1156 | 0.240 |
Why?
|
Osteoclasts | 1 | 2008 | 713 | 0.230 |
Why?
|
Phyllodes Tumor | 1 | 2024 | 55 | 0.230 |
Why?
|
Alcoholism | 1 | 2015 | 1981 | 0.230 |
Why?
|
Rhabdomyosarcoma | 2 | 2020 | 358 | 0.220 |
Why?
|
Epithelial Cells | 3 | 2022 | 3701 | 0.220 |
Why?
|
14-3-3 Proteins | 2 | 2023 | 222 | 0.210 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2022 | 3554 | 0.200 |
Why?
|
Melanoma | 1 | 2020 | 5709 | 0.200 |
Why?
|
Wnt Proteins | 1 | 2006 | 725 | 0.190 |
Why?
|
Chorionic Villi | 1 | 2021 | 53 | 0.190 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 15471 | 0.190 |
Why?
|
RNA | 1 | 2011 | 2727 | 0.190 |
Why?
|
Fetal Proteins | 1 | 2021 | 99 | 0.190 |
Why?
|
World Health Organization | 2 | 2024 | 1327 | 0.190 |
Why?
|
Adenosarcoma | 1 | 2021 | 36 | 0.190 |
Why?
|
Matrix Attachment Region Binding Proteins | 1 | 2021 | 48 | 0.190 |
Why?
|
Pain | 1 | 2016 | 5100 | 0.190 |
Why?
|
Papillomaviridae | 2 | 2019 | 1140 | 0.190 |
Why?
|
Liposarcoma, Myxoid | 1 | 2021 | 60 | 0.180 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5864 | 0.180 |
Why?
|
Breast Diseases | 1 | 2024 | 442 | 0.180 |
Why?
|
Stromal Cells | 3 | 2024 | 1337 | 0.180 |
Why?
|
Molar | 1 | 2021 | 155 | 0.180 |
Why?
|
Giant Cells, Langhans | 1 | 2020 | 2 | 0.180 |
Why?
|
Mammography | 2 | 2008 | 2434 | 0.180 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 259 | 0.180 |
Why?
|
DNA Mutational Analysis | 5 | 2018 | 4123 | 0.180 |
Why?
|
Histone Acetyltransferases | 1 | 2022 | 335 | 0.170 |
Why?
|
Nuclear Proteins | 3 | 2022 | 5803 | 0.170 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2020 | 2848 | 0.170 |
Why?
|
Trophoblasts | 1 | 2021 | 223 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 362 | 0.170 |
Why?
|
Receptors, Progesterone | 2 | 2019 | 1159 | 0.170 |
Why?
|
Cyclin D1 | 1 | 2021 | 453 | 0.160 |
Why?
|
Retrospective Studies | 11 | 2024 | 81892 | 0.160 |
Why?
|
Mastectomy | 2 | 2018 | 1850 | 0.160 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2021 | 419 | 0.160 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2011 | 3811 | 0.160 |
Why?
|
Neoplasm Proteins | 2 | 2015 | 3608 | 0.160 |
Why?
|
DNA Copy Number Variations | 6 | 2023 | 2055 | 0.160 |
Why?
|
Receptors, Steroid | 1 | 2019 | 156 | 0.150 |
Why?
|
Genes, Homeobox | 1 | 2020 | 289 | 0.150 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2019 | 202 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2016 | 1408 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 566 | 0.150 |
Why?
|
Microsatellite Instability | 1 | 2022 | 726 | 0.150 |
Why?
|
Combined Modality Therapy | 3 | 2022 | 8559 | 0.150 |
Why?
|
DNA, Neoplasm | 2 | 2014 | 1748 | 0.150 |
Why?
|
DNA | 1 | 2011 | 7214 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2018 | 8664 | 0.140 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2023 | 710 | 0.140 |
Why?
|
Rhabdoid Tumor | 1 | 2019 | 211 | 0.140 |
Why?
|
Mutagenesis | 2 | 2012 | 1229 | 0.140 |
Why?
|
Point Mutation | 3 | 2018 | 1595 | 0.140 |
Why?
|
Young Adult | 9 | 2024 | 60110 | 0.130 |
Why?
|
North America | 1 | 2020 | 1290 | 0.130 |
Why?
|
Microtubule-Associated Proteins | 1 | 2021 | 1073 | 0.130 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2021 | 737 | 0.130 |
Why?
|
DNA-Binding Proteins | 4 | 2023 | 9618 | 0.130 |
Why?
|
Vimentin | 1 | 2016 | 257 | 0.130 |
Why?
|
Cell Differentiation | 3 | 2021 | 11684 | 0.120 |
Why?
|
Laminectomy | 1 | 2016 | 226 | 0.120 |
Why?
|
Hysterectomy | 1 | 2021 | 866 | 0.120 |
Why?
|
Quinolones | 1 | 2019 | 389 | 0.120 |
Why?
|
Receptor, Bradykinin B1 | 1 | 2014 | 11 | 0.120 |
Why?
|
Ovary | 1 | 2020 | 965 | 0.120 |
Why?
|
Cytodiagnosis | 1 | 2019 | 453 | 0.120 |
Why?
|
Sequence Analysis, RNA | 6 | 2023 | 2041 | 0.120 |
Why?
|
Phenols | 1 | 2019 | 523 | 0.120 |
Why?
|
Genes, Reporter | 1 | 2019 | 1524 | 0.120 |
Why?
|
Lymph Node Excision | 1 | 2021 | 1273 | 0.120 |
Why?
|
Cytoplasm | 1 | 2019 | 1505 | 0.120 |
Why?
|
Histocytochemistry | 1 | 2015 | 699 | 0.120 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13593 | 0.110 |
Why?
|
Lymphocytes | 2 | 2020 | 2614 | 0.110 |
Why?
|
Gallium Radioisotopes | 1 | 2014 | 195 | 0.110 |
Why?
|
Tumor Burden | 2 | 2018 | 1913 | 0.110 |
Why?
|
Reproducibility of Results | 5 | 2024 | 20244 | 0.110 |
Why?
|
Metaplasia | 1 | 2014 | 326 | 0.110 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2011 | 317 | 0.110 |
Why?
|
Databases, Factual | 2 | 2020 | 8095 | 0.110 |
Why?
|
Mutation | 8 | 2016 | 30266 | 0.100 |
Why?
|
Autoimmunity | 1 | 2020 | 1360 | 0.100 |
Why?
|
Computational Biology | 2 | 2017 | 3562 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1616 | 0.100 |
Why?
|
Mastectomy, Segmental | 1 | 2018 | 960 | 0.100 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2013 | 205 | 0.100 |
Why?
|
Fatal Outcome | 2 | 2014 | 1836 | 0.100 |
Why?
|
Chromosomes, Human | 1 | 2014 | 438 | 0.100 |
Why?
|
Transcription Factors | 4 | 2023 | 12174 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3671 | 0.100 |
Why?
|
Diagnostic Errors | 1 | 2019 | 1281 | 0.100 |
Why?
|
Genes, Neoplasm | 2 | 2012 | 371 | 0.090 |
Why?
|
Societies, Medical | 1 | 2024 | 3967 | 0.090 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2013 | 428 | 0.090 |
Why?
|
Genotype | 4 | 2021 | 13048 | 0.090 |
Why?
|
Organometallic Compounds | 1 | 2014 | 648 | 0.090 |
Why?
|
Arthritis, Psoriatic | 1 | 2014 | 219 | 0.090 |
Why?
|
Cohort Studies | 5 | 2021 | 41800 | 0.090 |
Why?
|
Myometrium | 1 | 2011 | 174 | 0.090 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2015 | 489 | 0.090 |
Why?
|
Spermatogenesis | 1 | 2011 | 260 | 0.090 |
Why?
|
Paraffin Embedding | 1 | 2011 | 306 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2021 | 5323 | 0.090 |
Why?
|
Microscopy | 1 | 2015 | 909 | 0.090 |
Why?
|
Pancreatic Neoplasms | 1 | 2008 | 5443 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2960 | 0.090 |
Why?
|
Cell Nucleus | 1 | 2019 | 2885 | 0.090 |
Why?
|
Chromosome Aberrations | 2 | 2014 | 1780 | 0.090 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2011 | 239 | 0.090 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12563 | 0.090 |
Why?
|
Formaldehyde | 1 | 2011 | 361 | 0.080 |
Why?
|
Loss of Heterozygosity | 1 | 2012 | 663 | 0.080 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2011 | 329 | 0.080 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2010 | 218 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4064 | 0.080 |
Why?
|
Cell Line, Tumor | 5 | 2019 | 17174 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 5 | 2024 | 6546 | 0.080 |
Why?
|
Receptor, IGF Type 1 | 1 | 2011 | 384 | 0.080 |
Why?
|
Adolescent | 7 | 2024 | 89247 | 0.080 |
Why?
|
Granulosa Cell Tumor | 1 | 2009 | 76 | 0.080 |
Why?
|
Cell Proliferation | 2 | 2023 | 10486 | 0.080 |
Why?
|
DNA, Viral | 1 | 2015 | 2205 | 0.080 |
Why?
|
Gene Regulatory Networks | 3 | 2012 | 1752 | 0.080 |
Why?
|
Infertility, Male | 1 | 2011 | 398 | 0.080 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2013 | 856 | 0.080 |
Why?
|
Mice, Transgenic | 2 | 2019 | 9564 | 0.080 |
Why?
|
Testis | 1 | 2011 | 784 | 0.080 |
Why?
|
Immunoglobulin G | 1 | 2020 | 4568 | 0.070 |
Why?
|
Shock, Cardiogenic | 1 | 2013 | 711 | 0.070 |
Why?
|
Risk | 2 | 2018 | 9621 | 0.070 |
Why?
|
Antigens, CD | 2 | 2016 | 4032 | 0.070 |
Why?
|
Phenotype | 4 | 2023 | 16735 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3836 | 0.070 |
Why?
|
Ontario | 2 | 2022 | 403 | 0.070 |
Why?
|
Estrogen Receptor alpha | 2 | 2009 | 581 | 0.070 |
Why?
|
Spermatozoa | 1 | 2011 | 631 | 0.070 |
Why?
|
Databases, Genetic | 1 | 2014 | 1758 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2019 | 3473 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6805 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3238 | 0.070 |
Why?
|
Nucleotides | 1 | 2009 | 455 | 0.070 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2011 | 701 | 0.070 |
Why?
|
Collagen Type III | 1 | 2007 | 92 | 0.070 |
Why?
|
Male | 16 | 2023 | 365249 | 0.070 |
Why?
|
Genome, Human | 4 | 2013 | 4456 | 0.070 |
Why?
|
Cell Movement | 1 | 2019 | 5216 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13699 | 0.070 |
Why?
|
Evolution, Molecular | 2 | 2012 | 1894 | 0.070 |
Why?
|
Microarray Analysis | 1 | 2009 | 755 | 0.070 |
Why?
|
Intermediate Filament Proteins | 1 | 2007 | 262 | 0.070 |
Why?
|
Myocarditis | 1 | 2013 | 803 | 0.060 |
Why?
|
Psoriasis | 1 | 2014 | 926 | 0.060 |
Why?
|
Hypothalamus | 1 | 2011 | 1004 | 0.060 |
Why?
|
Algorithms | 2 | 2024 | 14199 | 0.060 |
Why?
|
Immunoenzyme Techniques | 1 | 2008 | 1705 | 0.060 |
Why?
|
Stem Cells | 2 | 2008 | 3540 | 0.060 |
Why?
|
Genomics | 3 | 2023 | 5928 | 0.060 |
Why?
|
Survival Rate | 3 | 2020 | 12873 | 0.060 |
Why?
|
Autopsy | 1 | 2008 | 1013 | 0.060 |
Why?
|
Occupational Medicine | 1 | 1985 | 116 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4593 | 0.060 |
Why?
|
Cell Count | 1 | 2008 | 1833 | 0.060 |
Why?
|
Alleles | 2 | 2012 | 6901 | 0.060 |
Why?
|
Time Factors | 3 | 2017 | 40266 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2012 | 9081 | 0.060 |
Why?
|
Signal Transduction | 2 | 2012 | 23652 | 0.060 |
Why?
|
Risk Factors | 3 | 2018 | 74971 | 0.050 |
Why?
|
Disease Progression | 5 | 2013 | 13677 | 0.050 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2011 | 1248 | 0.050 |
Why?
|
Homozygote | 2 | 2023 | 1779 | 0.050 |
Why?
|
Colon | 1 | 2011 | 1804 | 0.050 |
Why?
|
Animals | 10 | 2019 | 169408 | 0.050 |
Why?
|
In Situ Hybridization | 1 | 2007 | 1904 | 0.050 |
Why?
|
Cell Separation | 1 | 2008 | 1728 | 0.050 |
Why?
|
Pregnancy | 2 | 2023 | 30175 | 0.050 |
Why?
|
Extracellular Matrix Proteins | 1 | 2007 | 835 | 0.050 |
Why?
|
Lasers | 1 | 2007 | 952 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4356 | 0.050 |
Why?
|
Peptides | 1 | 2014 | 4353 | 0.050 |
Why?
|
Carcinoma in Situ | 1 | 2008 | 788 | 0.050 |
Why?
|
Endometriosis | 1 | 2010 | 874 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6085 | 0.050 |
Why?
|
Forkhead Transcription Factors | 1 | 2009 | 1625 | 0.050 |
Why?
|
Ribonuclease III | 1 | 2023 | 271 | 0.050 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2005 | 392 | 0.050 |
Why?
|
Receptors, Androgen | 1 | 2008 | 1091 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2017 | 65485 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 3 | 2022 | 2813 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9264 | 0.050 |
Why?
|
DEAD-box RNA Helicases | 1 | 2023 | 385 | 0.040 |
Why?
|
Myocardium | 1 | 2013 | 4790 | 0.040 |
Why?
|
Models, Statistical | 2 | 2012 | 5107 | 0.040 |
Why?
|
Antibodies | 1 | 2008 | 2422 | 0.040 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22381 | 0.040 |
Why?
|
Testosterone | 1 | 2011 | 2494 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 1602 | 0.040 |
Why?
|
Lung | 1 | 2019 | 10097 | 0.040 |
Why?
|
Mitotic Index | 1 | 2020 | 162 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2009 | 2592 | 0.040 |
Why?
|
Mice | 6 | 2019 | 82074 | 0.040 |
Why?
|
Necrosis | 1 | 2024 | 1621 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18366 | 0.040 |
Why?
|
Neprilysin | 1 | 2022 | 487 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 2 | 2016 | 1064 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 18065 | 0.040 |
Why?
|
Incidence | 1 | 2017 | 21545 | 0.040 |
Why?
|
Steroids | 1 | 2024 | 938 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2023 | 1498 | 0.040 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2022 | 633 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6673 | 0.040 |
Why?
|
Infant | 1 | 2020 | 36541 | 0.040 |
Why?
|
Child | 3 | 2024 | 80969 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3811 | 0.030 |
Why?
|
Child, Preschool | 1 | 2020 | 42684 | 0.030 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3951 | 0.030 |
Why?
|
Proteins | 1 | 2011 | 6011 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2012 | 16051 | 0.030 |
Why?
|
Liver | 1 | 2011 | 7579 | 0.030 |
Why?
|
Neoplasms | 2 | 2014 | 22390 | 0.030 |
Why?
|
HEK293 Cells | 2 | 2014 | 4291 | 0.030 |
Why?
|
Histiocytosis | 1 | 2013 | 39 | 0.030 |
Why?
|
STAT1 Transcription Factor | 1 | 2015 | 344 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 36861 | 0.030 |
Why?
|
Histiocytes | 1 | 2013 | 97 | 0.030 |
Why?
|
Estrogens | 1 | 2020 | 1537 | 0.030 |
Why?
|
Myoblasts, Skeletal | 1 | 2013 | 74 | 0.030 |
Why?
|
Gene Expression | 3 | 2011 | 7602 | 0.030 |
Why?
|
Lymphocytosis | 1 | 2013 | 121 | 0.030 |
Why?
|
Muscle Cells | 1 | 2013 | 195 | 0.030 |
Why?
|
RNA, Messenger | 3 | 2013 | 12809 | 0.030 |
Why?
|
Hypertension | 4 | 1988 | 8615 | 0.030 |
Why?
|
Heart Failure, Systolic | 1 | 2013 | 134 | 0.020 |
Why?
|
Serum | 1 | 2013 | 207 | 0.020 |
Why?
|
Allelic Imbalance | 1 | 2012 | 77 | 0.020 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2012 | 147 | 0.020 |
Why?
|
Hemorrhage | 1 | 2024 | 3465 | 0.020 |
Why?
|
Sperm Maturation | 1 | 2011 | 22 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 906 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2909 | 0.020 |
Why?
|
Proteomics | 1 | 2005 | 3913 | 0.020 |
Why?
|
Microscopy, Video | 1 | 2011 | 241 | 0.020 |
Why?
|
Survival Analysis | 2 | 2015 | 10115 | 0.020 |
Why?
|
INDEL Mutation | 1 | 2012 | 267 | 0.020 |
Why?
|
Cytosine | 1 | 2012 | 213 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2011 | 162 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 440 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 751 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1839 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2013 | 808 | 0.020 |
Why?
|
Protein Phosphatase 2 | 1 | 2012 | 231 | 0.020 |
Why?
|
Automation | 1 | 2012 | 589 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2011 | 867 | 0.020 |
Why?
|
Signal Recognition Particle | 1 | 2009 | 46 | 0.020 |
Why?
|
Taq Polymerase | 1 | 2009 | 20 | 0.020 |
Why?
|
Camptothecin | 1 | 2013 | 600 | 0.020 |
Why?
|
Histones | 1 | 2020 | 2603 | 0.020 |
Why?
|
Ultrasonography | 1 | 2023 | 6001 | 0.020 |
Why?
|
Genes, p16 | 1 | 2009 | 159 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2009 | 381 | 0.020 |
Why?
|
Clone Cells | 1 | 2012 | 1670 | 0.020 |
Why?
|
Neurocirculatory Asthenia | 1 | 1988 | 9 | 0.020 |
Why?
|
BRCA2 Protein | 1 | 2013 | 803 | 0.020 |
Why?
|
RNA Editing | 1 | 2009 | 150 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2011 | 2560 | 0.020 |
Why?
|
Gene Dosage | 1 | 2012 | 1222 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2015 | 5342 | 0.020 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2009 | 303 | 0.020 |
Why?
|
Propanolamines | 1 | 1988 | 164 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 6213 | 0.020 |
Why?
|
Genes, ras | 1 | 2009 | 665 | 0.020 |
Why?
|
Fibrocystic Breast Disease | 1 | 2007 | 103 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2016 | 2747 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2012 | 1105 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2007 | 424 | 0.020 |
Why?
|
Sequence Analysis, Protein | 1 | 2007 | 265 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 6232 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14751 | 0.020 |
Why?
|
Occupational Diseases | 2 | 1988 | 1458 | 0.020 |
Why?
|
Gene Frequency | 1 | 2012 | 3625 | 0.020 |
Why?
|
Blood Viscosity | 1 | 1985 | 125 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2011 | 1320 | 0.010 |
Why?
|
Telomerase | 1 | 2009 | 753 | 0.010 |
Why?
|
Mice, SCID | 1 | 2009 | 2631 | 0.010 |
Why?
|
Carcinoembryonic Antigen | 1 | 2005 | 338 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2008 | 2475 | 0.010 |
Why?
|
DNA Repair | 1 | 2013 | 2054 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2009 | 3102 | 0.010 |
Why?
|
Acute Disease | 1 | 2013 | 7245 | 0.010 |
Why?
|
Genetic Markers | 1 | 2009 | 2604 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2007 | 2749 | 0.010 |
Why?
|
Species Specificity | 1 | 2007 | 2419 | 0.010 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1658 | 0.010 |
Why?
|
Physical Exertion | 1 | 1985 | 668 | 0.010 |
Why?
|
Rabbits | 1 | 2008 | 4774 | 0.010 |
Why?
|
Glucose | 1 | 2013 | 4352 | 0.010 |
Why?
|
Echocardiography | 1 | 2013 | 5046 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4148 | 0.010 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 933 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2023 | 20776 | 0.010 |
Why?
|
Sports | 1 | 1985 | 703 | 0.010 |
Why?
|
Guanethidine | 1 | 1978 | 14 | 0.010 |
Why?
|
Base Sequence | 1 | 2009 | 12430 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12093 | 0.010 |
Why?
|
Software | 1 | 2012 | 4480 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2011 | 7609 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54950 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18454 | 0.010 |
Why?
|
Inflammation | 1 | 2015 | 10869 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 22294 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2009 | 7885 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 12798 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2013 | 39394 | 0.010 |
Why?
|
Propranolol | 1 | 1988 | 493 | 0.000 |
Why?
|
Rheology | 1 | 1985 | 348 | 0.000 |
Why?
|
Stress, Psychological | 1 | 1978 | 4542 | 0.000 |
Why?
|
Drug Evaluation | 1 | 1978 | 642 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 1988 | 8055 | 0.000 |
Why?
|